Breaking News

Biogen to Acquire Reata Pharmaceuticals in $7.3B Deal

Will gain SKYCLARYS, the first and only approved treatment for Friedreich’s ataxia, and a portfolio of products for a range of neurological diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Inc. entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. for approximately $7.3 billion.   Reata is advancing development of therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is the first and only approved treatment for Friedreich’s ataxia (FA), with a commercial launch underway, and European regulatory review ongoing. Reata is also developing a portfolio of innovative pro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters